Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
Titel:
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
Auteur:
Elghawy, Omar Barsouk, Adam Reed-Guy, Lauren Stalker, Margaret Sussman, Jonathan Robinson, Kyle Kosteva, John Singh, Aditi Cohen, Roger B. Langer, Corey Ciunci, Christine D'Avella, Christopher Sun, Lova Marmarelis, Melina E. Aggarwal, Charu